{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:10:30Z","timestamp":1686661830724},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.blre.2010.03.001","type":"journal-article","created":{"date-parts":[[2010,4,2]],"date-time":"2010-04-02T08:25:16Z","timestamp":1270196716000},"page":"91-100","source":"Crossref","is-referenced-by-count":10,"title":["How best to use new therapies in multiple myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"David","family":"Dingli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2010.03.001_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.286.5439.531","article-title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","volume":"286","author":"Golub","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.blre.2010.03.001_bib3","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2010.03.001_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2010.03.001_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1053\/sonc.2001.28601","article-title":"Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma","volume":"28","author":"D'Amato","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib8","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2010.03.001_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib14","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib15","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib17","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2010.03.001_bib18","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib20","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib21","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib22","doi-asserted-by":"crossref","unstructured":"Kumar SK, Mikhael JR, Buadi FK, et al. The management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clinic Proceedings. 2009;84:1095\u20131110.","DOI":"10.4065\/mcp.2009.0603"},{"key":"10.1016\/j.blre.2010.03.001_bib23","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ijc.20491","article-title":"Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients","volume":"112","author":"Garcia-Sanz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2010.03.001_bib24","first-page":"25","article-title":"Plasma cell labeling index","volume":"113","author":"Greipp","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.blre.2010.03.001_bib25","first-page":"199","article-title":"Chromosome 13 deletion in myeloma","volume":"246","author":"Shaughnessy","year":"1999","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.blre.2010.03.001_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-0609.2006.00807.x","article-title":"Chromosomal abnormalities of young multiple myeloma patients (<45yr) are not different from those of other age groups and are independent of stage according to the International Staging System","volume":"78","author":"Sagaster","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib28","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","article-title":"Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system","volume":"107","author":"Dingli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib30","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib31","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","article-title":"Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials","volume":"27","author":"Harousseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation-2008.1.306","article-title":"Induction therapy in multiple myeloma","volume":"2008","author":"Harousseau","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2010.03.001_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","article-title":"Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma","volume":"6","author":"Dingli","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.blre.2010.03.001_bib34","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib35","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib36","doi-asserted-by":"crossref","first-page":"3593a","DOI":"10.1182\/blood.V110.11.3593.3593","article-title":"Thalidomide combinations improves response rates: results from the MRC IX study","volume":"110","author":"Morgan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib37","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1200\/JCO.2007.11.7879","article-title":"Relationship between depth of response and outcome in multiple myeloma","volume":"25","author":"Dingli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/leu.2008.2","article-title":"A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy","volume":"22","author":"Bergsagel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib39","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2008.40","article-title":"Making progress in treating multiple myeloma with total therapies: issue of complete remission and more","volume":"22","author":"Barlogie","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine\u2013doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2010.03.001_bib42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib45","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib46","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2010.03.001_bib47","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29\u201337.","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"10.1016\/j.blre.2010.03.001_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8504","article-title":"Randomized trial of lenalidomide plus hig-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the eastern Cooperative Oncology group: analysis of response, survival, and outcome","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bmt.1704173","article-title":"Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma","volume":"32","author":"Ghobrial","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2010.03.001_bib51","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2010.03.001_bib52","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib53","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","article-title":"Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients","volume":"22","author":"Mazumder","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib54","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","article-title":"Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma","volume":"22","author":"Paripati","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","article-title":"Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma","volume":"14","author":"Mark","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2010.03.001_bib56","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2010.03.001_bib57","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V99.11.4079","article-title":"Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib58","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib59","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2009.07803.x","article-title":"Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma","volume":"146","author":"Jagannath","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib60","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2010.03.001_bib61","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics","volume":"25","author":"Rosinol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.450.450","article-title":"VELCADE\/Dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 trial","volume":"110","author":"Harousseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib63","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10245330701214236","article-title":"Bortezomib in combination with thalidomide\u2013dexamethasone for previously untreated multiple myeloma","volume":"12","author":"Wang","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2010.03.001_bib65","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.73.73","article-title":"Bortezomib (Velcade)\u2013Thalidomide\u2013Dexamethasone (VTD) vs Thalidomide\u2013Dexamethasone in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"110","author":"Cavo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib66","article-title":"Lenalidomide, bortezomib and dexamethasone (Rev\/Vel\/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1\/2 study","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib68","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib69","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2141.2008.07572.x","article-title":"Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma","volume":"44","author":"Popat","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib70","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib71","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.leukres.2006.08.002","article-title":"Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed\/refractory multiple myeloma","volume":"31","author":"Chang","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2010.03.001_bib72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib73","doi-asserted-by":"crossref","first-page":"160a","DOI":"10.1182\/blood.V112.11.160.160","article-title":"Bortezomib (BOR) and high dose melphalan (HDM) as conditioning regimen before autologous stem cell transplantation (ASCT) for de novo multiple myeloma (MM): final results of the IFM Phase II study Vel\/Mel","volume":"112","author":"Roussel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib74","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2010.03.001_bib75","first-page":"1095","article-title":"Hemopoietic stem cell transplant for multiple myeloma (MM)","volume":"7","author":"Barlogie","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib76","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib77","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.656.656","article-title":"Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX maintenance randomisation","volume":"112","author":"Morgan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib79","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib80","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","article-title":"Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial","volume":"111","author":"Abdelkefi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib81","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.58.58","article-title":"First analysis of the Australasian Leukemia and Lymphoma Group (ALLG) Trial of Thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6)","volume":"108","author":"Spencer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib82","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2007.12.185","article-title":"Phase I\/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma","volume":"14","author":"Schiller","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2010.03.001_bib84","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2010.03.001_bib85","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2010.03.001_bib86","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide\u2013dexamethasone compared to melphalan\u2013prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib87","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2010.03.001_bib88","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib89","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2010.03.001_bib90","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.649.649","article-title":"Melphalan+prednisone versus melphalan+prednisone+thalidomide in induction therapy for multiple myeloma in elderly patients; final analysis of the Dutch Cooperative Group HOVON 49 Study","volume":"112","author":"Wijermans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib92","article-title":"A randomized placebo controlled study with melphalan\/prednisone\/thalidomide: quality of life and toxicity","volume":"93","author":"Gulbrandsen","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2010.03.001_bib93","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.615.615","article-title":"Melphalan and Prednisone (MP) versus Melphalan, Prednisone and Thalidomide (MPT) as initial therapy for previously untreated elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis of five randomized controlled trials","volume":"114","author":"Kapoor","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib94","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2014Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib95","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib96","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2778.2778","article-title":"Superior outcomes associated with complete response: analysis of the phase III VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"112","author":"Harousseau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib97","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.448.448","article-title":"Bortezomib, pegylated-piposoma-doxorubicin and dexamethasone followed by melphalan 100mg\/m2 in elderly newly diagnosed patients: an interim analysis","volume":"110","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib98","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.651.651","article-title":"Bortezomib (Velcade)-Melphalan-Prednisone (VMP) versus Velcade-Thalidomide-Prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylator or an immunomodulatory agent?","volume":"112","author":"Mateos","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib99","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.652.652","article-title":"A prospective randomized phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma. patients","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib100","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib101","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib102","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib103","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib104","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2010.03.001_bib105","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.03.001_bib106","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2010.03.001_bib107","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2010.03.001_bib108","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X10000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X10000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T13:12:41Z","timestamp":1591189961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X10000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0268960X10000111"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2010.03.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}